JP2015231997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015231997A5 JP2015231997A5 JP2015132999A JP2015132999A JP2015231997A5 JP 2015231997 A5 JP2015231997 A5 JP 2015231997A5 JP 2015132999 A JP2015132999 A JP 2015132999A JP 2015132999 A JP2015132999 A JP 2015132999A JP 2015231997 A5 JP2015231997 A5 JP 2015231997A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- histidine
- mannitol
- formulation according
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 9
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 5
- 229960001838 canakinumab Drugs 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000004067 bulking agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000003571 reporter gene assay Methods 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170884.4 | 2008-12-10 | ||
| EP08170884A EP2196476A1 (en) | 2008-12-10 | 2008-12-10 | Antibody formulation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540063A Division JP6143416B2 (ja) | 2008-12-10 | 2009-12-09 | 抗体製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018102715A Division JP2018168158A (ja) | 2008-12-10 | 2018-05-29 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015231997A JP2015231997A (ja) | 2015-12-24 |
| JP2015231997A5 true JP2015231997A5 (OSRAM) | 2016-02-25 |
Family
ID=40637230
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540063A Active JP6143416B2 (ja) | 2008-12-10 | 2009-12-09 | 抗体製剤 |
| JP2015132999A Withdrawn JP2015231997A (ja) | 2008-12-10 | 2015-07-01 | 抗体製剤 |
| JP2018102715A Withdrawn JP2018168158A (ja) | 2008-12-10 | 2018-05-29 | 抗体製剤 |
| JP2020133477A Active JP7286595B2 (ja) | 2008-12-10 | 2020-08-06 | 抗体製剤 |
| JP2023085464A Pending JP2023109938A (ja) | 2008-12-10 | 2023-05-24 | 抗体製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540063A Active JP6143416B2 (ja) | 2008-12-10 | 2009-12-09 | 抗体製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018102715A Withdrawn JP2018168158A (ja) | 2008-12-10 | 2018-05-29 | 抗体製剤 |
| JP2020133477A Active JP7286595B2 (ja) | 2008-12-10 | 2020-08-06 | 抗体製剤 |
| JP2023085464A Pending JP2023109938A (ja) | 2008-12-10 | 2023-05-24 | 抗体製剤 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20110236398A1 (OSRAM) |
| EP (4) | EP2196476A1 (OSRAM) |
| JP (5) | JP6143416B2 (OSRAM) |
| KR (2) | KR20170044211A (OSRAM) |
| CN (3) | CN102245639B (OSRAM) |
| AU (1) | AU2009324371B2 (OSRAM) |
| BR (1) | BRPI0922730A2 (OSRAM) |
| CA (1) | CA2745938C (OSRAM) |
| CL (1) | CL2011001406A1 (OSRAM) |
| CO (1) | CO6361952A2 (OSRAM) |
| CY (2) | CY1117735T1 (OSRAM) |
| DK (2) | DK2376533T3 (OSRAM) |
| EC (1) | ECSP11011192A (OSRAM) |
| ES (2) | ES2579835T3 (OSRAM) |
| HR (2) | HRP20160754T1 (OSRAM) |
| HU (2) | HUE028408T2 (OSRAM) |
| IL (3) | IL264316B2 (OSRAM) |
| LT (1) | LT3072906T (OSRAM) |
| MA (1) | MA33023B1 (OSRAM) |
| MX (1) | MX2011006242A (OSRAM) |
| MY (2) | MY166050A (OSRAM) |
| NZ (1) | NZ592918A (OSRAM) |
| PE (1) | PE20120342A1 (OSRAM) |
| PL (2) | PL3072906T3 (OSRAM) |
| PT (2) | PT3072906T (OSRAM) |
| RU (2) | RU2745601C2 (OSRAM) |
| SI (2) | SI2376533T1 (OSRAM) |
| SM (1) | SMT201600222B (OSRAM) |
| TN (1) | TN2011000229A1 (OSRAM) |
| WO (1) | WO2010066762A1 (OSRAM) |
| ZA (1) | ZA201103362B (OSRAM) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| EA201892184A1 (ru) | 2010-03-01 | 2019-03-29 | БАЙЕР ХЕЛЬСКЕР ЛЛСи | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| TWI621625B (zh) | 2010-09-17 | 2018-04-21 | 巴克斯歐塔公司 | 在弱酸性至中性ph中經由具有組胺酸的水性調配物穩定免疫球蛋白 |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重v區類抗體蛋白質之用途 |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| FI123630B (fi) | 2011-10-24 | 2013-08-30 | Teknologian Tutkimuskeskus Vtt | Menetelmä NFC-kalvojen valmistamiseksi alustoille |
| AP2014007680A0 (en) | 2011-12-02 | 2014-06-30 | Novartis Ag | Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| AU2013221635B2 (en) * | 2012-02-16 | 2017-12-07 | Santarus, Inc. | Anti-VLA1 (CD49a) antibody pharmaceutical compositions |
| RU2664473C2 (ru) * | 2012-03-16 | 2018-08-17 | Регенерон Фармасьютикалз, Инк. | ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| UA115789C2 (uk) * | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CN109999195A (zh) * | 2012-09-20 | 2019-07-12 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| CA2891556A1 (en) * | 2012-11-16 | 2014-05-22 | Novartis Ag | Use of il-1 beta binding antibodies for treating peripheral arterial disease |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| UY35460A (es) * | 2013-03-15 | 2014-10-31 | Bayer Healthcare Llc | Formulaciones de anticuerpos anti-receptor de prolactina |
| TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| JP6707469B2 (ja) * | 2014-05-28 | 2020-06-10 | ノノ インコーポレイテッド | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
| RU2017107847A (ru) * | 2014-09-03 | 2018-10-03 | Медиммун Лимитед | Стабильный состав на основе антитела к il-4r-альфа |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| JP2017537084A (ja) | 2014-11-12 | 2017-12-14 | トラコン ファーマシューティカルズ、インコーポレイテッド | 抗エンドグリン抗体及びその用途 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| ES2823279T3 (es) * | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab |
| HRP20210945T1 (hr) * | 2016-06-27 | 2021-09-17 | Morphosys Ag | Formulacije protutijela anti-cd19 |
| KR20190032436A (ko) * | 2016-07-21 | 2019-03-27 | 노파르티스 아게 | 폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도 |
| BR112019005328A2 (pt) * | 2016-09-27 | 2019-06-18 | Fresenius Kabi Deutschland Gmbh | composição farmacêutica líquida |
| JOP20190103B1 (ar) | 2016-11-18 | 2023-09-17 | Astellas Pharma Inc | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري |
| WO2018234879A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
| US20200207848A1 (en) * | 2017-09-13 | 2020-07-02 | Novartis Ag | Use of il-1b binding antibodies for the treatment of alcoholic hepatitis |
| MX2020009935A (es) * | 2018-03-23 | 2021-01-08 | Abbvie Deutschland | Formulaciones acuosas y estables de anticuerpos anti-tau. |
| WO2019221269A1 (ja) | 2018-05-17 | 2019-11-21 | アステラス製薬株式会社 | 抗ヒトMUC1抗体Fabフラグメント、ペプチドリンカー及び/又は配位子を含む複合体 |
| CN117752825A (zh) | 2018-10-10 | 2024-03-26 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| CN120241997A (zh) * | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业(上海)股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| WO2022135395A1 (zh) * | 2020-12-22 | 2022-06-30 | 百奥泰生物制药股份有限公司 | 稳定的抗体制剂及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| SI1516628T1 (sl) | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| TW200514783A (en) | 1999-09-22 | 2005-05-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| JP4955185B2 (ja) | 2000-06-29 | 2012-06-20 | アボット・ラボラトリーズ | 二重特異性抗体ならびに作製方法および使用方法 |
| EP1336410A4 (en) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| DK2335725T3 (en) * | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| AU2006207901A1 (en) * | 2005-01-28 | 2006-08-03 | Wyeth | Stabilized liquid polypeptide formulations |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| KR100996801B1 (ko) * | 2005-03-08 | 2010-11-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항-MAdCAM 항체 조성물 |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| PL1940465T3 (pl) | 2005-10-26 | 2013-01-31 | Novartis Ag | Nowe zastosowanie przeciwciał anty-IL-1beta |
| CN201044845Y (zh) * | 2006-10-28 | 2008-04-09 | 李开元 | 自动注射器 |
| CA2671968A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
| MX2009010179A (es) * | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
-
2008
- 2008-12-10 EP EP08170884A patent/EP2196476A1/en not_active Ceased
-
2009
- 2009-12-09 US US13/133,843 patent/US20110236398A1/en not_active Abandoned
- 2009-12-09 NZ NZ592918A patent/NZ592918A/xx unknown
- 2009-12-09 PL PL16162699T patent/PL3072906T3/pl unknown
- 2009-12-09 MY MYPI2014002791A patent/MY166050A/en unknown
- 2009-12-09 WO PCT/EP2009/066675 patent/WO2010066762A1/en not_active Ceased
- 2009-12-09 CN CN200980149644.4A patent/CN102245639B/zh active Active
- 2009-12-09 MX MX2011006242A patent/MX2011006242A/es active IP Right Grant
- 2009-12-09 DK DK09764858.8T patent/DK2376533T3/en active
- 2009-12-09 PE PE2011001179A patent/PE20120342A1/es active IP Right Grant
- 2009-12-09 CN CN201410730219.7A patent/CN104399076B/zh active Active
- 2009-12-09 SI SI200931459A patent/SI2376533T1/sl unknown
- 2009-12-09 HR HRP20160754TT patent/HRP20160754T1/hr unknown
- 2009-12-09 KR KR1020177009939A patent/KR20170044211A/ko not_active Ceased
- 2009-12-09 RU RU2015132431A patent/RU2745601C2/ru not_active Application Discontinuation
- 2009-12-09 KR KR1020117015821A patent/KR101762966B1/ko active Active
- 2009-12-09 HR HRP20211899TT patent/HRP20211899T1/hr unknown
- 2009-12-09 CN CN202111066425.9A patent/CN114225022A/zh active Pending
- 2009-12-09 HU HUE09764858A patent/HUE028408T2/en unknown
- 2009-12-09 DK DK16162699.9T patent/DK3072906T3/da active
- 2009-12-09 MY MYPI2011002067A patent/MY157772A/en unknown
- 2009-12-09 ES ES09764858.8T patent/ES2579835T3/es active Active
- 2009-12-09 JP JP2011540063A patent/JP6143416B2/ja active Active
- 2009-12-09 EP EP16162699.9A patent/EP3072906B1/en active Active
- 2009-12-09 HU HUE16162699A patent/HUE056626T2/hu unknown
- 2009-12-09 EP EP20197506.7A patent/EP3792282A1/en active Pending
- 2009-12-09 CA CA2745938A patent/CA2745938C/en active Active
- 2009-12-09 LT LTEP16162699.9T patent/LT3072906T/lt unknown
- 2009-12-09 RU RU2011127913/15A patent/RU2563179C2/ru active
- 2009-12-09 IL IL264316A patent/IL264316B2/en unknown
- 2009-12-09 PT PT161626999T patent/PT3072906T/pt unknown
- 2009-12-09 AU AU2009324371A patent/AU2009324371B2/en active Active
- 2009-12-09 PT PT97648588T patent/PT2376533T/pt unknown
- 2009-12-09 SI SI200932153T patent/SI3072906T1/sl unknown
- 2009-12-09 MA MA33984A patent/MA33023B1/fr unknown
- 2009-12-09 ES ES16162699T patent/ES2900624T3/es active Active
- 2009-12-09 PL PL09764858.8T patent/PL2376533T3/pl unknown
- 2009-12-09 EP EP09764858.8A patent/EP2376533B1/en active Active
- 2009-12-09 BR BRPI0922730A patent/BRPI0922730A2/pt not_active Application Discontinuation
-
2011
- 2011-05-09 ZA ZA2011/03362A patent/ZA201103362B/en unknown
- 2011-05-10 TN TN2011000229A patent/TN2011000229A1/fr unknown
- 2011-05-16 IL IL212922A patent/IL212922B/en active IP Right Grant
- 2011-06-09 CL CL2011001406A patent/CL2011001406A1/es unknown
- 2011-06-10 CO CO11072271A patent/CO6361952A2/es not_active Application Discontinuation
- 2011-07-08 EC EC2011011192A patent/ECSP11011192A/es unknown
-
2012
- 2012-08-15 US US13/586,185 patent/US8623367B2/en active Active
-
2015
- 2015-07-01 JP JP2015132999A patent/JP2015231997A/ja not_active Withdrawn
-
2016
- 2016-06-30 CY CY20161100603T patent/CY1117735T1/el unknown
- 2016-07-11 SM SM201600222T patent/SMT201600222B/it unknown
-
2018
- 2018-05-29 JP JP2018102715A patent/JP2018168158A/ja not_active Withdrawn
-
2020
- 2020-07-16 US US16/930,475 patent/US20200384108A1/en not_active Abandoned
- 2020-08-06 JP JP2020133477A patent/JP7286595B2/ja active Active
- 2020-08-10 IL IL276622A patent/IL276622A/en unknown
-
2021
- 2021-12-07 CY CY20211101069T patent/CY1124844T1/el unknown
-
2023
- 2023-05-24 JP JP2023085464A patent/JP2023109938A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015231997A5 (OSRAM) | ||
| TWI725973B (zh) | 抗-cgrp抗體調配物 | |
| Dumpa et al. | Stability of vaccines | |
| JP7473603B2 (ja) | 液体医薬組成物 | |
| JP2024178197A (ja) | 液体医薬組成物 | |
| HRP20241131T1 (hr) | Visokokoncentrirane formulacije inhibitornih antitijela masp-2 niske viskoznosti, pribori i metode | |
| JP2021504372A5 (OSRAM) | ||
| JP2014514346A5 (OSRAM) | ||
| RU2015132431A (ru) | Составы, содержащие антитела | |
| JP7229999B2 (ja) | ダプトマイシン製剤 | |
| JP2016520075A5 (OSRAM) | ||
| CN101631563B (zh) | 含有流感疫苗的冻干制剂及其制备方法 | |
| JP2019504086A5 (OSRAM) | ||
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| JP2019509311A5 (OSRAM) | ||
| JP2015519382A5 (OSRAM) | ||
| JP2013079270A5 (OSRAM) | ||
| RU2011151286A (ru) | Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств | |
| JP2016535065A (ja) | 熱安定性ワクチン製剤及びマイクロニードル | |
| JP2019504882A5 (OSRAM) | ||
| JP2017531682A5 (OSRAM) | ||
| JP2016505572A5 (OSRAM) | ||
| RU2016105462A (ru) | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| JP2017514868A5 (OSRAM) |